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Abstract
Background: In cancer care, a GP's work is rarely defined clearly. Our aim was to assess GPs'
work with cancer patients in France and in Norway, where the roles of the GP and the organization
of the system are rather different.
Findings: A questionnaire with 40 closed-ended questions about GP involvement in diagnosis,
treatment, follow-up and terminal care was constructed and mailed to samples of GPs. The patients
had seen the doctor at least once over the past year. In France 1679 and in Norway 386 individual
patient questionnaires were completed. GPs have a major role in the diagnosis of cancer, and this
role varies according to cancer type. The GPs participated actively in different phases of follow-up
after cancer treatment. Low response rates do not allow direct comparison between countries,
but higher PSA screening rates in France seem to increase the percentage of patients diagnosed
after screening rather than after a clinical suspicion. Interaction between GPs and specialists during
cancer treatment and follow-up was important in both countries.
Conclusion: Both in France and in Norway GPs participate actively in cancer care. Early clinical
diagnosis is a challenge. More research is needed about how GPs can improve their early diagnostic
work. Organisational issues may influence cancer responsibilities for the GP, and national health
systems should be challenged to look at possible new roles for GPs in cancer care. Medical training,
both pre- and post-graduate, should prepare doctors for collaboration between primary and
secondary care, particularly important in cancer care.
Background
In cancer care, diagnosis [1-3], follow-up [4,5] and pallia-
tive care fall within the responsibility of the GP. Despite
this, the work of the GP in this area is often considered as
residual compared to that of specialists. In France and
Norway, patients are free to choose their doctor, but in
Norway the gatekeeper role of the GP is more pronounced
and the circuit of medical professionals and health care
institutions is more predetermined, depending on the
patient's problem. We studied the diagnostic and thera-
peutic responsibility sphere of the GPs in the two coun-
tries with regard to cancer.
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Methods
Design and setting
The questionnaire [see Additional file 1] and the protocol
used were established jointly by GPs in Norway and GPs
and sociologists in France. Initially, British, Belgian and
Italian GPs participated in discussions, and a preliminary
questionnaire was tested in five countries [6]. The current
team concentrated on two countries: France and Norway.
The questionnaire was originally in French and was trans-
lated into Norwegian by one of the authors (KH). An
intra-observer test-retest reliability study [7] was per-
formed in Norway where GPs completed the same ques-
tionnaire twice with one month's interval for the same 15
patients. The re-test was not announced when the ques-
tionnaire was first sent out. Total agreement in 660
answers was 88.2% (95% CI 85.7-90.6%). This was con-
sidered satisfactory.
In the present study, the data were drawn from the cancer
patients' routine medical records. Their GPs answered the
40 closed-ended questions on the patients' care (preven-
tion, diagnostic process, choice of medical team and ini-
tial treatment, monitoring of the disease and its side-
effects, end-of-life if relevant) and on the doctor-patient
relationship (length of the relationship, psychological
and social support, contact with the family). The patient
inclusion protocol consisted of two conditions:
- having or having had cancer, irrespective of the location
of the disease, or of its stage or whether the patient was
still alive;
- having consulted or seen the doctor at least once in the
year preceding the survey.
In France, the GPs were asked to select the five first
patients on the doctor's list of consultations, who met the
inclusion criteria; while in Norway the GPs were asked to
select one or two patients they remembered, given the
inclusion criteria.
Data collection
In France the postal questionnaires were sent out in Janu-
ary of 2005 to a 10% sample of GPs practicing in main-
land France (n = 5056). This was a random sample
identified by the national health fund (CNAMTS). In Nor-
way the postal questionnaires were sent out in October
2005 to a 10% random sample of South Norwegian GPs
and to all the GPs in the sparsely populated North Nor-
way (n = 801). This sample was supplied by the Norwe-
gian Medical Association (NMA). In France, 1679 eligible
patient questionnaires were filled in by 348 GPs (7% of
the GP sample), on average 4.8 questionnaires per
respondent. In Norway, 386 eligible patient question-
naires were filled in by 292 GPs (39% of the GP sample)
with an average of 1.3 questionnaires per respondent.
The data were plotted and analysed using SPSS. Because of
the differences in the instructions given to the doctors in
the two countries, and also because of low response rates,
we are not presenting statistical comparisons between the
two countries. Chi square tests and t-tests are used for
within-country analyses.
Ethical approval
The survey protocol was accepted by the French Data Pro-
tection Authority (CNIL). No patients were contacted, and
personal data recorded were limited to sex, year of birth
and type of cancer. Clearance by Ethical Research Com-
mittees was therefore not deemed necessary.
Results
The cancer patients
Age and sex of the patients are presented in table 1. Mean
age at diagnosis was 61 years in France and 60 years in
Norway; males were older than females in both countries.
Health status of the patients at the time of the most recent
consultation is shown in table 2. Three types of cancer -
breast, colorectal, and male genital organs - predomi-
nated, with a majority of breast cancers among French
patients (27% France, 17% Norway) and colorectal can-
cers for Norwegian patients (13% France, 21% Norway).
182 (11%) French and 12 Norwegian patients (3%) had
their second cancer.
The GP-patient relationship
80% of French patients and 73% of Norwegian patients
consulted the GP before their cancer was diagnosed. In
9% of French cases and 18% of Norwegian cases, the can-
Table 1: Patient sex and age in years
France (N = 1697) Norway (N = 386)
Females Males All P1 Females Males All P1
Mean age at diagnosis 58 63 61 <0.001 57 63 60 <0.001
Median age at diagnosis 58 65 62 58 65 61
Mean age at last follow-up 63 66 65 <0.001 60 66 63 <0.001
Median age at last follow-up 64 68 67 61 68 63
1. Within-country difference between females and males, t-test.BMC Research Notes 2009, 2:200 http://www.biomedcentral.com/1756-0500/2/200
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cer diagnosis and the first meeting with this GP took place
in the same year.
Prevention at the GP's surgery
GPs commonly discuss risks relating to life-style, environ-
ment or family medical history with their patients. For the
cancer patients in our study, such preventive information
before diagnosis had been given to 42% of Norwegian
patients and 30% of French patients. Previous preventive
action in the form of screening or case finding without a
presumption of cancer on clinical grounds had been car-
ried out for about half of the patients in both countries.
Establishing a diagnosis (table 3)
In both countries, GPs reported to a large extent being
involved in the diagnosis. The GPs considered themselves
to be at the origin of the process of discovering the cancer
for 78% of the patients in France and for 83% in Norway.
This varied for different forms of cancer (P < 0.001 for
France, P = 0.003 for Norway), and was most marked for
colorectal cancer and male genital cancer in both coun-
tries. For breast cancer, only about six of every ten cases
had been diagnosed by GPs in both countries. In France,
more males than females were diagnosed by the GP (P <
0.001). The patients diagnosed by GPs were older, 62 vs
57 years (P < 0.001) in France, and 61 vs 57 years in Nor-
way (P = 0.03).
In most cases the cancer was discovered after a clinical or
complementary procedure, based on a suspicion of cancer
(59% France, 73% Norway) and usually prescribed by the
GP him/herself. The rate of chance discovery was similar,
16% in France and 14% in Norway. Diagnosis after
screening of an asymptomatic patient was 19% among
French patients and 9% among Norwegian patients. The
screening difference is mainly due to a much higher per-
centage of screened cases of male genital cancer, mainly of
the prostate. Male genital cancer constituted 14% of all
cases in both countries. In France 45% of these patients
had been diagnosed after screening while in Norway this
was the case for 14%.
GPs' role in therapy (table 3)
Choice of the medical team differs structurally because the
existence of pre-established treatment trajectories in Nor-
way determines the choice for a majority of cancer
patients. In France, a more or less "compulsory" team was
imposed for only 15% of patients. The choice can be
based on the GP's personal relations and/or the team's
reputation (49% France, 14% Norway), while taking into
account the patient's and his/her family's wishes, if they
are expressed (29% France, 12% Norway).
Involvement in follow-up after cancer treatment (table 4)
During the first year of the follow-up, the GP was involved
in the care for about three quarters of French patients and
for about two thirds of Norwegian patients, mainly in col-
laboration with the hospital team and with other profes-
sionals. The GPs continued to be involved in follow-up
after the first year for the great majority of their patients.
Table 2: Clinical status of the patients1
France Norway
Clinical status N % N %
Well, no current cancer treatment 686 41.0 105 27.4
Undergoing treatment for cancer 638 38.1 171 44.6
In terminal phase 104 6.2 29 7.6
Dead 247 14.7 78 20.4
Sum 1675 100 383 100
1Data missing for 22 French patients and 3 Norwegian patients
Table 3: GP's role in diagnosis and therapy
France Norway
Diagnostic process N% N %
Diagnosis after clinical suspicion 994 59 282 73
Chance Discovery 270 16 54 14
Diagnosis after screening in asymptomatic patient 313 19 32 9
Implication of GP in the diagnostic procedure 1310 78 319 83
Personal GP took diagnostic initiative 1223 73 257 67
Another GP took diagnostic initiative 87 5 62 16
Patient feared having cancer 455 27 33 9
Therapy
Organisation of health care decided treatment team 259 15 309 80
Treatment team reputation contributed to choice 820 49 54 14
Patient or family contributed to choice 489 29 47 12
GP implicated in choice of cancer treatment 223 13 15 4
GP implicated in dealing with side effects of treatment 910 54 180 47
GP implicated in administering chemotherapy 68 4 34 9
GP = General PractitionerBMC Research Notes 2009, 2:200 http://www.biomedcentral.com/1756-0500/2/200
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In both countries GPs gave considerable psychological
support to their patients, including conversations, assist-
ance with administrative procedures and, to a lesser
extent, coordination of home care. A majority of the
patients continued consulting a GP for other ailments
than their cancer.
GP involvement for patients with progressive disease 
(table 5)
For 561 French and 208 Norwegian patients, the GPs
reported that the cancer had progressed or relapsed. GPs
participated in the care in the majority of these cases. One
fourth of all French patients and one third of all Norwe-
gian patients received morphine prescribed by their GP;
the difference can be explained by the greater proportion
of dead and terminal patients in Norway. No differences
were found within either country for different diagnostic
groups or for sex or age. In many cases, collaboration with
hospital colleagues had been established in these situa-
tions. In both countries approximately half of the patients
spent their entire terminal phase either at home or in a
retirement facility [8].
Discussion
Questions of method
There are no validated questionnaires assessing GPs' role
in cancer care. To collect data about cancer patients, we
therefore gathered a panel of European GPs to develop the
questionnaire based on information about individual
patients available in medical records, and which could be
filled in by the GP. A test-retest study in Norway found the
reliability satisfactory. Most questions seem to have been
readily understood in the two countries. Recall bias has
been reduced by the use of medical records when the
information was reported, and the internal validity seems
to be satisfactory in that the answers give a rather compre-
hensive picture of what French and Norwegian GPs do in
cancer care. For consideration of further validity the ques-
tionnaire would have to be tested in other countries.
Table 4: Participation in follow-up by the general practitioner during or after primary cancer treatment
France
N = 1679
Norway
N = 386
Procedure N% N %
GP implicated in follow-up 1st year after primary treatment 1277 76 252 65
GP implicated in follow-up after first year 1179 781 215 731
Important patient-doctor talk 1309 78 327 85
Social-administrative help (sick leave, home based care...) 963 57 259 67
Co-ordination of home care 369 22 67 17
Treatment of non-cancer disease 1203 72 247 64
Non-cancer treatment led to contact with cancer therapist 281 17 45 12
1 Of 1519 French patients and 295 Norwegian patients where this was relevant one year after primary treatment
Table 5: GP participation in progressive disease, treatment with opiates, place where the person received terminal care and died, and 
contact with the family after the patient's death
France Norway
N%N%
GP participated in care after clinical aggravation or relapse 392 701 138 661
Opiates prescribed for home use 2 399 24 122 32
By GP alone 214 54 42 35
By GP + hospital/pain team 100 25 40 33
By hospital/pain team 85 21 40 33
Location of terminal care3:
Home or home institution 220 70 86 80
Special unit for palliative care 32 10 12 11
Hospital 144 45 49 46
Hereof only in hospital 99 31 20 19
Dead: 247 15 78 20
Hereof at home 100 41 21 27
Contact with family after death 217 88 55 71
1 Of 561 French patients and 208 Norwegian patients with progressive disease or relapse.
2 Data missing for 3 Norwegian patients
3 Counting patients in terminal phase or deadBMC Research Notes 2009, 2:200 http://www.biomedcentral.com/1756-0500/2/200
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The strength of our approach is that the GPs were report-
ing what happened for specific patients rather than
expressing their opinions about what happens in general.
The time required for GPs to fill in five patient question-
naires probably explains the low rate of response by
French GPs. The better response rate in Norway may
reflect that only one or two cancer cases were asked for,
and that GPs were not asked to search records in order to
find patients. However, it probably contributed to ine-
qualities in the two samples of cancer patients and thus to
some of the observed patient differences. Norwegian GPs
selected, to a greater extent than their French counterparts,
patients who were more present in their minds. This could
be patients being actively treated for cancer, those in ter-
minal phase or those who had recently passed away,
rather than older patients who had recovered. Going back
in the list of consultations, as the French protocol
required, may have minimized the effect of memory. Also,
including more files per GP may have increased the prob-
ability of including patients who were in remission or
cured. The response rate in both countries is far too low to
be representative for either all GPs or for all cancer
patients. This severely limits the validity of country com-
parisons and is why we have avoided statistical between-
countries comparisons. However, it does not invalidate
findings of a high level of cancer care activities in both
countries, and several of our findings are consistent with
English data [9]. For Norwegian doctors, the sex distribu-
tion was no different for responders and non-responders.
For non-responders, we do not have further data. In
France female doctors were slightly overrepresented
among responders, while there was no difference in mean
age.
GPs' participation in diagnosis
A previous study from England has suggested that the role
of the GP in cancer care is important [9]. The variation in
the GP's diagnostic role associated with cancer type was
found in this study as well. The essential role of GPs in the
discovery of cancer is confirmed in our study. Norwegian
GPs generally have access in their own group practices to
a greater repertoire of supplementary tests than French
GPs, who must refer patients for blood tests. This may
have had some impact on detecting cancer on clinical
grounds. Nevertheless, GPs' involvement in diagnostics
was shown to be common in both countries. Differences
in how our national samples were collected tend to intro-
duce bias in any comparisons. However, we think that the
considerable difference in the proportion of screened
cases of prostate cancer suggests that French GPs are more
prone to use PSA screening, a hotly debated issue with no
clear recommendations in France and a negative recom-
mendation in Norway. This difference may explain that
the GP's diagnostic role was more important for males in
France, but not in Norway.
Good quality GP work during the diagnostic process is
important even if this is less relevant for the substantial
minority of cases diagnosed by screening or presenting as
emergencies. The clinical challenge for the GP is consider-
able, emphasized by a British study which for six cancers
showed longer diagnostic delay for patients having seen
their GP prior to diagnosis than for those who did not
[10]. Possibilities for improvement must be considered in
the context of the low predictive value of suspected symp-
toms and the challenges attached to the use of watchful
waiting and appropriate thresholds for referral. The low
specificity of possible cancer symptoms is well known and
is a major challenge for GPs and other doctors consulted
prior to diagnosis [11]. GPs know that age is a major risk
factor for cancer, and our study confirms that attention to
this is justified in that older patients more than younger
patients consulted a GP before diagnosis. Fear of cancer in
consulting patients should be taken seriously, but is gen-
erally of little value in making a cancer diagnosis [12].
GPs' participation in treatment
After the initial treatment, largely defined and carried out
in a hospital, psychosocial follow-up and treatment of
non-cancer ailments are important tasks for the GP. Treat-
ing side-effects is common. Our study did not ask about
follow-up for specific cancers. Others have shown that
clinical follow-up of breast cancer by the GP does not
increase delay in diagnosing relapse [13]. GPs can also
play an important role in the follow-up of colorectal can-
cer [14].
In the terminal phase, GP involvement is desirable and
possible [15]. French GPs are more often involved in treat-
ing patients at home than are Norwegian GPs, although
their role is important in both countries. The system in
Norway seems to allow for a return to hospital or to a spe-
cialized service more easily than in France.
Conclusion
French and Norwegian GPs participate actively in care for
cancer patients. Cancer diagnostics is a challenge for the
GP when a patient fears or the GP suspects cancer. This is
consistent in both France and Norway, and it calls for
more research about how GPs can improve their early
diagnostic work. The organisation of care differs, and pre-
established treatment trajectories or a predefined role as a
personal doctor may encourage other cancer care tasks for
the GP than a system that emphasizes the maintenance of
the patient's and doctor's freedom of choice. Further
national studies could explore possible new tasks for the
GP in cancer care. Most patients in both countries return
to their GP some time after finishing treatment, either for
non-cancer ailments or for progression of cancer symp-
toms. In the latter case, GPs and hospital doctors need toPublish with BioMed Central    and   every 
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cooperate and this should be reflected in their medical
training.
Abbreviations used
GP: General practitioner.
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